摘要
目的:探究二甲双胍治疗2型糖尿病患者对丝裂原活化蛋白激酶p38(p38-MAPK)、白细胞介素-17(IL-17)表达水平和胰岛β细胞功能的影响。方法:选取2018年1月-2021年1月本院收治的100例2型糖尿病患者作为研究对象,按随机法分为对照组(n=50)和观察组(n=50),对照组给予常规治疗,观察组在对照组基础上给予二甲双胍治疗,观察两组的p38MAPK、IL-17表达水平及胰岛β细胞功能改善情况。结果:治疗后观察组p38-MAPK和IL-17明显低于对照组,差异均有统计学意义(P<0.05)。治疗后观察组早期胰岛素分泌指数(EISI)、修正胰岛β细胞分泌指数(MBCI)、胰岛β细胞功能指数(HOMA-β)、C肽曲线下面积(AUC;)、胰岛素曲线下面积(AUC;)均明显高于对照组,差异均有统计学意义(P<0.05);观察组血糖曲线下面积(AUC;)明显低于对照组,差异均有统计学意义(P<0.05)。结论:应用二甲双胍治疗2型糖尿病,有助于改善患者胰腺β细胞功能,并可显著降低患者p38-MAPK和IL-17表达水平。
Objective:To explore the effect of Metformin on the expression of mitogen activated protein kinase p38 (p38-MAPK) and interleukin-17 (IL-17) and islet β cell function in patients with type 2 diabetes mellitus.Method:A total of 100 patients with type 2 diabetes from January 2018 to January 2021 were selected and they were randomly divided into the control group (n=50) and the observation group (n=50).The control group received routine treatment,while the observation group was given Metformin treatment on the basis of the control group.The expression level of p38MAPK,IL-17,and improvement of islet β cell function in the two groups were observed.Result:After treatment,p38-MAPK and IL-17 in the observation group were significantly lower than those in the control group,the differences were statistically significant (P<0.05).After treatment,the early insulin secretion index (EISI),modified β cell function index (MBCI),islet β cell function index (HOMA-β),the area under the C-peptide curve (AUC;),the area under the insulin curve (AUC;) were significantly higher than those in the control group,the differences were statistically significant (P<0.05);and the area under the blood glucose curve (AUC;) in the observation group was significantly lower than that in the control group,the difference was statistically significant (P<0.05).Conclusion:Metformin treatment for patients with type 2 diabetes can improve the islet β cell function,and can significantly reduce the expression levels of p38-MAPK and IL-17.
作者
邓伟国
林庆志
DENG Weiguo;LIN Qingzhi(Siming Hospital of the First Affiliated Hospital of Xiamen University,Xiamen 361003,China;不详)
出处
《中外医学研究》
2021年第35期26-29,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
